Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABAA receptors
Pharmacology Biochemistry and Behavior · 2024-05 · 238 · 173734
DOI: 10.1016/j.pbb.2024.173734 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacology Biochemistry and Behavior, 2024-05. Verfasst von Renu Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, GD Goenka University, Gurugram, Haryana 122103, India. Hauptthemen laut MEDLINE: Depression, Postpartum, Pregnanolone, Pyrazoles. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Postpartum depression [PPD] is a prevalent and debilitating mood disorder that affects mothers in the weeks to months after childbirth. Zuranolone (Zurzuvae) is a novel pharmaceutical agent that was approved by the US FDA on 4 August 2023 for the management of PPD. This review article provides a comprehensive overview of zuranolone, focusing on its dosing, chemistry, mechanism of action, clinical trials, adverse drug reaction, and overall conclusion regarding its utility in the management of PPD. It also discusses the recommended dosing strategies to achieve optimal efficacy while minimizing adverse effects as the dosage regimen of zuranolone is critical for its therapeutic application. Moreover, it gives insights into neurobiological pathways involved in PPD. METHODOLOGY: Data from randomized controlled trials and observational studies was collected to provide a comprehensive understanding of zuranolone in the management and treatment of PPD. CONCLUSION: Zuranolone represents a promising therapeutic option for women suffering from postpartum depression. However, ongoing research and post-marketing surveillance are essential to further elucidate its long-term safety and efficacy. The integration of zuranolone into clinical practice may significantly improve the quality of life for mothers facing the challenges of postpartum depression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, GD Goenka University, Gurugram, Haryana 122103, India.
- Department of Pharmacy, GD Goenka University, Gurugram, Haryana 122103, India; Amity Institute of Pharmacy, Amity University, Sector - 125, Noida, Uttar Pradesh-201301, India. Electronic address: richadhingra67@gmail.co…
Zitieren
APA
Sharma, R., Bansal, P., Saini, L., Sharma, N., & Dhingra, R. (2024). Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABAA receptors. Pharmacology Biochemistry and Behavior, 238, 173734. https://doi.org/10.1016/j.pbb.2024.173734
Vancouver
Sharma R, Bansal P, Saini L, Sharma N, Dhingra R. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABAA receptors. Pharmacology Biochemistry and Behavior. 2024;238:173734. doi:10.1016/j.pbb.2024.173734
BibTeX
@article{Sharma2024,
author = {Sharma, Renu and Bansal, Pranjal and Saini, Lokesh and Sharma, Nidhi and Dhingra, Richa},
title = {Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABAA receptors},
journal = {Pharmacology Biochemistry and Behavior},
year = {2024},
volume = {238},
pages = {173734},
doi = {10.1016/j.pbb.2024.173734}
}
EUVIMED